Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ulrike Söling"'
Autor:
Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian Martin Kurbacher, Ursula Vehling-Kaiser, Dagmar Sent, Peter Klare, Volker Hagen, Marco Chiabudini, Julia Falkenstein, Martin Indorf, Eva Runkel, Karin Potthoff
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods In this randomized, cross
Externí odkaz:
https://doaj.org/article/0b607e2f74894218bc58a733d5c46416
Autor:
Matthias Groschek, Corinne Vannier, Sina Grebhardt, Hans Ulrich Siebenbach, Ulrike Söling, Tobias Dechow, Timo Behlendorf, Ali Aldaoud, Karin Potthoff, Wolfgang Knauf, Henning Eschenburg, Richard A. Hansen
Publikováno v:
European Journal of Haematology. 108:133-144
Background Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor and treatment options are limited. While pomalidomide plus low-dose dexamethasone (POM/DEX) has demonstra
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
J. Sahlmann, Ulrike Söling, Corinne Vannier, Norbert Marschner, Leonora Houet, Pauline Wimberger, C Brucker, Manfred Welslau, Oliver J. Stoetzer, Johannes Meiler, Steffen Dörfel, Karin Potthoff
Publikováno v:
Cancer Research. 80:P5-11
Background: The pivotal PALOMA trials investigated the combination of the cyclin-dependent kinase 4/6 inhibitor palbociclib with letrozole as first-line treatment or with fulvestrant after prior endocrine therapy in patients with advanced HR+/HER2- b
Publikováno v:
Oncology research and treatment. 45(7-8)
Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient’s quality of life (QoL), delayi
Autor:
M Chiabudini, Christian M. Kurbacher, E Runkel, J Falkenstein, Karin Potthoff, C Maintz, Ulrike Söling, L Rieger, Thomas Decker, A Hahn
Publikováno v:
Cancer Research. 79:P6-21
For patients (pts) with advanced HR+/HER2- breast cancer various treatment options exist. Endocrine therapy or chemotherapy are the recommended 1st-line treatment options according to international guidelines. With comparable efficacy, it is of utmos
Autor:
Sina Grebhardt, Arnd Nusch, Richard A. Hansen, Ulrike Söling, Johanna Harde, Karin Potthoff, Norbert Marschner, Christoph Salat
Publikováno v:
Clinical Breast Cancer. 18:e1323-e1337
One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials ha
Autor:
Antje Hahn, Julia Falkenstein, Dagmar Sent, Peter Klare, Christian M. Kurbacher, Ulrike Söling, Martin Indorf, Ursula Vehling-Kaiser, Volker Hagen, Marco Chiabudini, Karin Potthoff, Christoph Maintz, Eva Diana Runkel, Thomas Decker
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Cancer
BMC Cancer
Background The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods In this randomized, cross-over pha
Autor:
Peter Vandenberghe, Ulrike Söling, Ulrich Germing, Catharina Müller-Thomas, Uwe Platzbecker, Katayoon Shirneshan, Nicolaus Kröger, Corinna Strupp, Detlef Haase, Christina Ganster, Christel Müller, Gudrun Göhring, Julie Schanz, Mar Mallo, Michael Lübbert, Kiyoyuki Ogata, Claudia Haferlach, Francesc Solé, Barbara Hildebrandt, Katharina Götze, Tilman Steinmetz, Sophie Raynaud
Publikováno v:
GENES CHROMOSOMES & CANCER
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer generally assigned to poor risk fea
Autor:
Uwe Platzbecker, Barbara Hildebrandt, Detlef Haase, Roxana Schaab, Ulrike Söling, Frank Lange, Francesc Solé, Friederike Braulke, Ulrike Bacher, Julie Schanz, Laura Palomo, Lea Naomi Eder, Ulrich Germing, Anna Mies, Maike Nickelsen, Jennifer Kaivers, Gesine Bug, Bertram Glass, Nicolaus Kröger, Christina Ganster, Bernd Hertenstein, Marc Talló Parra, Konstanze Döhner, Katayoon Shirneshan, Ahmet H. Elmaagacli
Publikováno v:
Blood. 134:3007-3007
Introduction: Complex aberrant karyotypes (CK, ≥3 cytogenetic aberrations, CA) are associated with an unfavorable prognosis and an increased AML transformation rate in MDS. However, even MDS with CK (CK-MDS) are heterogeneous in terms of genetic pr